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Abstract
Background: More than 90% of human immunodeficiency virus (HIV)‐
infected patients will develop at least one type of skin disorder during the
course of the disease. The prevalence and severity of skin disease
commonly seen in HIV‐infected patients has decreased in the era of com-
bination antiretroviral therapy (cART). Few studies in Ethiopia have shown
the magnitude of skin problems among adult patients on cART. The aim of
this study is to describe the pattern of skin disease among adult patients
who are on cART.
Methods: Cross‐sectional observational study at ALERT Hospital from April
2018 to November 2018. Patterns of clinically diagnosed skin diseases
were summarized descriptively.
Result: A total of 572 patients were evaluated. In total, 412 (72%) were
female and the mean age of study participants was 40 (SD = 10.4). The
median CD4 count at the time of diagnosis and start of cART were 178 (R
5‐2000) and 168 cells/μl (R 5‐1327), respectively. The mean duration of
cART was 8 (SD = 3) years. 89.3% of patients were on first line and 7% on
second line of cART regimen. Noninfectious inflammatory skin disorders
(40.9%) were the most common concomitant diagnosis followed by infec-
tious diseases (34.9%), infestation (7.7%), pigmentary disorders (6.3%) and
cutaneous drug eruption (0.7%), respectively. Among the inflammatory skin
disorders, 56.5% presented with eczema. One patient had Kaposi sarcoma.
Conclusion: Noninfectious inflammatory skin disorders are the most com-
mon concomitant skin disease in HIV‐infected patients, with eczema being
most prevalent. Infectious skin diseases were also common presentations.
In our study, AIDS‐defining skin conditions were rare.
1 | INTRODUCTION
Cutaneous diseases are among the first recognized
manifestations of human immunodeficiency virus (HIV)
infection. Some conditions such as Kaposi's sarcoma
and eosinophilic folliculitis are specific indicators of
HIV, while other cutaneous diseases, while not being
unique to patients living with HIV, may show more
severe presentations, present atypically or be less
responsive to treatment than in HIV‐negative pa-
tients.1,2 Given the relative ease of examination of the
skin, and with most skin diseases being amenable to
diagnosis by inspection alone, evaluation of skin re-
mains an important tool in the diagnosis and follow up
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of HIV infection.3 This is particularly important in
resource poor countries such as Ethiopia. More than
90% of HIV‐infected patients will develop at least one
type of skin disorder during the course of their HIV
infection1 and these can reflect the underlying immune
status.
The number of people dying from AIDS‐related
diseases globally fell from a peak of 2.3 million in
2005 to an estimated 0.7 million in 2019.4 This
encouragingly steep fall is a function of reduced HIV
prevalence and increased access to combination anti-
retroviral therapy (cART). International guidelines have
recognized that early treatment of HIV infection im-
proves outcomes.5 Access to antiretroviral therapy has
improved in the last decade for patients living with HIV
in low‐ and middle‐income countries with the number
of patients receiving antiretroviral therapy increasing
more than 30‐fold (from 300 000 in 2002 to 9.7 million
in 2012), and a resulting increase in life expectancy.4,6
In Ethiopia, the annual number of new HIV infections
similarly shows a declining trend. Incident HIV infection
in adults has fallen from an estimated 13 394 in 2016
to 11 613 in 2019. Around 415 580 adults and 21 385
children were on cART and treatment coverage for
adults has now reached 75% and 34% for children.7
The encouraging fall in HIV prevalence and mor-
tality means that there has been a decrease in the
prevalence and severity of infectious, inflammatory and
neoplastic skin diseases that were commonly seen with
HIV infection in the pre‐cART era. Nevertheless, we
have observed that skin diseases are still commonly
seen in our patients in Ethiopia receiving cART. This
may be due to poor HIV control, adverse effects of
cART drugs, immune reconstitution inflammatory syn-
drome or increased life expectancy.8 As few studies
have examined the mucocutaneous manifestation of
HIV infection outside Western countries and none has
examined the pattern of skin disease in Ethiopia after
the introduction of cART, we here describe the pattern
of skin disease in adult patients living with HIV
receiving cART at our dermatology clinic.
2 | METHODS
We performed a cross‐sectional observational study of
skin diseases in patients living with HIV and receiving
cART who were seen at ALERT hospital. ALERT (All
Africa Leprosy Rehabilitation and Training centre) is
located in Addis Ababa, Ethiopia, and serves as the
main referral hospital and training centre for skin dis-
ease for the whole of Ethiopia. Over 6000 HIV‐infected
patients on cART are registered and followed up at the
outpatient HIV clinic at ALERT. Between April 2018
and November 2018, adult patients in whom skin dis-
ease was noted by the HIV clinic medical staff, or who
self‐identified with skin disease, were referred to the
dermatology clinic. Patients had to be over the age of
18, with a diagnosis of HIV and have been on cART for
at least 6 months. A complete examination of the skin,
hair, nails and mucous membrane was conducted on all
referred patients by a trained dermatologist or senior
dermatology resident at ALERT. In most cases, a clinical
diagnosis of skin disease was made. Where available,
other HIV‐related parameters such as CD4 count and
viral load were collected. In cases of diagnostic uncer-
tainty, or where clinically indicated, relevant in-
vestigations, such as biopsy with a histopathological
examination, mycology and microbiology were per-
formed. Skin disorders were classified as: infection,
infestation, noninfectious inflammatory condition,
pigmentary abnormalities, cutaneous drug eruption and
miscellaneous skin condition to allow comparison with
previous surveys of Ethiopian skin disease.9 Data were
compiled and simple summary statistics performed
using SPSS version 23. Ethical approval was obtained
from the Armauer Hansen Research Institute/ALERT
Ethics Review Committee.
3 | RESULTS
A total of 660 HIV‐positive patients with skin disease
were referred to the dermatology clinic during the
study period. Of these, complete data were available on
572 patients. Four hundred twelve patients (72%) were
women and the mean age was 40 (SD = 10.4). All
referred patients had a skin condition diagnosed. Four
hundred ninety‐seven patients (86.9%) had one
What is already known about this
topic?
� Combination antiretroviral therapy has
dramatically changed the natural course of
HIV infection in Ethiopia.
� Skin disease is common in HIV infection in
Ethiopia.
� Little is known about patterns of skin disease
in cART‐treated Ethiopians with HIV.
What does this study add?
� Skin disease in cART‐treated HIV patient
mirrors that of the non‐HIV infected
population.
� AIDS defining skin disease is uncommon in
cART‐treated Ethiopian patients.
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condition, 71 (12.4%) had two, and 4 (0.7%) had three
conditions.
CD4 counts were available on 116 patients,
although these were not measured at the time of
diagnosis of skin disease, and we are thus not able to
identify links between CD4 count and incident skin
disease. Of these patients, median CD4 count at the
time of HIV diagnosis was 178 cells/μl (range, 5–2000)
and at the start of cART was 168 cells/μl (range, 5–
1327), respectively. Viral load data were available on
263 patients, of whom 242 had no detectable viral load.
The mean duration of cART in our cohort patient was 8
years. Five hundred eleven (89.3%) patients were on
first‐line cART regimen and 41 (7.2%) on second‐line
cART. Twenty (3.5%) further patients were on alter-
native regimen due to treatment failure or side effects
(Table 1). In around 96% of patients’ diagnosis was
made clinically. The most common additional investi-
gation done was KOH exam for fungal infection fol-
lowed by biopsy and skin slit smear test. A total of 680
mucocutaneous diagnoses were observed during the
course of the study (Table 2). Noninfectious inflam-
matory skin conditions were the most common diag-
nosis, seen in 40.9% of all cases, of which eczemas
(23.1%) were the most common diagnosis. Infectious
skin disease was observed in 34.8% cases, with der-
matophytosis (19%) being the most common diagnosis
(Table 3). Of the 129 patients with a fungal infection,
65 had viral load results and 11 of these had a
detectable viral load, comprising six with tinea corporis,
three with onychomycosis and two with tinea facie. The
pattern of fungal disease thus appeared similar in those
with and without a detectable viral load. Infestation,
pigmentary abnormalities, cutaneous drug eruption and
miscellaneous conditions were seen in 7.7%, 6.3%, 0.7%
and 9.5% of cases, respectively (Table 2). Only one
patient had Kaposi's sarcoma. There was no correlation
between different patterns of skin disease identified
when patients were stratified by CD4 count.
4 | DISCUSSION
This is the first study of prevalent skin disease in pa-
tients living with HIV infection in Ethiopia. Such studies
have been carried out in other geographical regions,
but the data here presented show the specific pattern
of disease in the Horn of Africa which may represent
both the background burden of skin disease and local
factors predisposing to this pattern of disease. We did
not measure the proportion of HIV‐infected patients
with concomitant skin disease, but instead the pattern
of skin disease in those with mucocutaneous involve-
ment. The robust data that we have generated will
allow for healthcare planning and alerts physicians to
conditions they should anticipate treating.
The effectiveness of cART has meant that even in
low‐ and middle‐income countries, HIV infection is a
chronic condition, and the patterns of skin disease seen
are more likely to represent the underlying population
pattern of skin disease rather than the specific HIV
defining skin conditions seen in the pre‐cART era.
We identified a relatively low number of AIDS‐
defining skin diseases at ALERT during the 7 months of
our study period. The most prevalent that we observed
were mild to moderate seborrheic eczema in 11% (64
cases, five with a detectable viral load), and pruritic
papular eruption in 8% (46 cases, six with detectable
viral load). Pruritic papular eruption has been reported
with a range of prevalence from 12% to 46% in Sub‐
TAB L E 1 Demographic characteristics (n = 572)
Variables
Age (mean, 1SD) 40 (10.4)
Sex (M: F) 1:3
ART duration in years (mean, SD) 8, 3
Mean CD4 count
At diagnosis of HIV (range) 178 (5–2000)
At start of cART (range) 168 (5–1327)
Viral load (number, %)
Not detected 217 (38%)
Detected 46 (8%)
Missing 309 (54%)
cART regimen (number, %)
First line 511 (89.5%)
Second line 41 (7%)
Other 20 (3.5%)





TAB L E 2 Dermatologic disease category
Disorder Number Percent
Noninfectious inflammatory 278 40.9%
Infectious 237 34.9%
Infestation 52 7.7%
Pigmentary abnormalities 43 6.3%
Cutaneous drug eruption 5 0.7%
Miscellaneous 65 9.5%
Total = 680 (number of diagnosis)
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Saharan Africa7 and was also the most prevalent in-
flammatory manifestation of HIV infection at 16% in an
Indian study.10 It thus remains relatively common
despite cART. Five drug rashes were seen, which is an
unusually low number but probably reflects the fact that
patients were seen in a routine clinic, and patients with
an acute drug rash would generally have been referred
urgently to their local hospital. Three drug rashes were
due to antibiotics (azithromycin, norfloxacin and cipro-
floxacin) and in the others wewere unable to identify the
offending drug. This is lower than 3.9% reported in
central Africa.11 No drug eruptions specifically due to
cART were seen, probably because such reactions
generally occur in the first few weeks after initiation of
therapy, and our cohort were well established on these
drugs. Eosinophilic folliculitis is usually seen with severe
immunosuppression but was only diagnosed in three of
our patients (one with a detectable viral load) which may
be an indicator of the success of cART in controlling
immunosuppression in this Ethiopian setting. A single
TAB L E 3 Prevalence of skin manifestation
Noninfectious disorders Infectious disorders
Disorder Number, % Disorder Number, %
Eczema 157, 23.1 Fungal 129,19
Seborrheic eczema 64 Tinea corporis 33
Allergic contact eczema 23 Onychomycosis 23
Atopic eczema 21 Tinea pedis 22
Discoid eczema 19 Tinea facie 18
Others 30 Vaginal candidiasis 8
Papulosquamous 20, 3 Oral trash 6
Lichen planus 15 Tinea capiti 5
Psoriasis 11 Others 14
Pityriasis rosea 1 Bacterial 43, 6.3
Pilosebaceous 20, 3 Furuncle 14
Rosacea 7 Bacterial folliculitis 11
Perioral dermatitis 4 Carbuncle 9
Alopecia areata 4 Leprosy 2
Acne 3 Others 7
Folliculitis decalvance 2 Viral 61, 8.9
Other inflammatory 91, 13.4 Genital wart 16
Pruritic papular eruption 46 Molluscum cotagiosum 11
Acute urticarial 15 Herpes zoster 10
Eosinophilic folliculitis 3 Common wart 9
Others 27 Plantar wart 8
Drug eruption 5, 0.7 Flat wart 8
Maculopapular 1 Others 3
Fixed drug eruption 1 Protozoal 4, 0.6
Stevens Johnson syndrome 1 Cutaneous leishmaniasis 2
Lichenoid 1 Mucocutaneous leishmaniasis 2
Urticarial 1 Infestation 52, 7.6%
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case of Kaposi sarcoma (KS) was diagnosed. In America
andEurope,KS is particularly prevalent inMenwhohave
SexwithMen (MSM)12 and thevery lowcase ratewe saw
may reflect the different epidemiology for HIV infection
in Africa, as well as good disease control with cART to
which KS responds.
Noninfectious inflammatory conditions as a group
were the most common skin disorders (40.9%), partic-
ularly eczemas (seborrheic dermatitis 11%, and
eczemas other than seborrheic dermatitis 16%). This
pattern of skin disease is not dissimilar to that of non‐
HIV‐infected Ethiopian skin patients. In the Derma-
tology Department of Black Lion Teaching Hospital in
Addis Ababa, eczemas make up 20%–25% of all adult
outpatient consultations, and skin infections and
infestations another 25%.9 The high prevalence of
inflammatory skin disease in our cART‐treated HIV‐
infected patients thus reflects the general Ethiopian
population's pattern of skin disease. The American
experience of patients on cART is that folliculitis and
prurigo nodularis are the most prevalent skin condi-
tions13; we suspect this may be due to a different
background pattern of skin disease. In Thailand, 61% of
patients had noninfectious inflammatory conditions,14
which is thus much closer to the Ethiopian than
American pattern of disease. The high prevalence of
women in our cohort (412, 72%) was also reported by
Salmani et al. in Nigeria and Glynn et al. in Kenya.1
Photosensitivity is common in cART‐treated patients in
temperate countries affecting 5%–8% of patients.15
Ethiopia is on the equator and mostly at an altitude of
around 2500 m, so has an extremely high UV insolation.
In the non‐HIV‐infected population, photodermatoses
are common, yet the only photosensitivity we detected
was actinic lichen planus in 2.2% of our cohort. This
surprising finding may be due to patients on cART be-
ing cautious of sun exposure. The incidence of psoriasis
is not affected in HIV‐infected population but the
presentation can be aggressive.8 Despite this, in our
study, only mild to moderate chronic plaque type of
psoriasis was seen in 1.2% of cases.
Infectious cutaneousdisorderswere the secondmost
common presentation in our study. Fungal infections
were the most common (129, 19%), similar to a Chinese
study that suggested that fungal infection might be
considered as a marker of disease progression.16 Tinea
corporis was most common as in a Nigerian study.1
Viral infections were the second most common
infectious conditions with genital warts being most
prevalent, followed by molluscum contagiosum. Zan-
canaro et al.13 reported an increased number of
molluscum contagiosum. Meys et al.17 also reported
that there is no demonstrable effect of cART in
reducing cutaneous warts. Cutaneous leishmaniasis is
endemic and highly prevalent in the highland area of
Ethiopia.18 The country has seen new outbreaks in
areas previously not known to be endemic, often with
coinfection by the HIV with rates reaching 5.6% of the
cases.19 It can present with atypical presentation in
patients living with HIV infection but the usual
manifestation is more frequent. In our study 0.6% of
cases were cutaneous leishmaniasis and we did not
observe any atypical manifestations of the disease.
Seven point six percent of patients had scabies in our
cohort, but this is probably similar to the healthy
population prevalence, as scabies was highly prevalent
throughout Ethiopia at the time of data collection. No
cases of crusted scabies were seen. We observed
unexpectedly low pigmentary changes, with no iden-
tified melanonychia although this is reported in pa-
tients on cART. Similarly, we only identified 4 (0.7%)
cases of xerosis despite other studies reporting mag-
nitudes as high as 75%.16 This may represent under-
reporting of xerosis or real changes in prevalence due
to local factors.
5 | LIMITATION
This is a cross‐sectional study and substantial propor-
tion of patients did not have a viral load measured;
therefore, it is difficult to establish an association be-
tween CD4 count, viral load and skin diseases within
this small‐scaled study. Future longitudinal studies will
be required to understand the trend of skin diseases
experienced by patients living with HIV as cART con-
tinues to evolve. The study is also limited to a single
referral centre at ALERT, therefore we cannot gener-
alize to other settings in Ethiopia.
6 | CONCLUSION
In this Ethiopian referral hospital, we observed a low
number of AIDS‐defining skin diseases in cART‐treated
HIV‐positive patients. Inflammatory and infectious skin
diseases broadly matched the background pattern of
skin disease in the general population. Noninfectious
inflammatory dermatoses were the most common skin
manifestations. Dermatophytosis and pruritic papular
eruption were commonly seen in patients with
detectable viral load despite treatment with cART.
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